Ultragenyx Pharmaceutical
RARE
228 hedge funds and large institutions have $3.14B invested in Ultragenyx Pharmaceutical in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 104 increasing their positions, 58 reducing their positions, and 40 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
79% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 58
14% more call options, than puts
Call options by funds: $18.3M | Put options by funds: $16M
12% more capital invested
Capital invested by funds: $2.81B → $3.14B (+$333M)
0.12% less ownership
Funds ownership: 96.9% → 96.78% (-0.12%)
8% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 40
2% less funds holding
Funds holding: 233 → 228 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$63.2M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$36.9M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$28.6M |
| 4 |
Millennium Management
New York
|
+$18.8M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$86.7M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$82.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$33.2M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$28.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26M |
RARE Hedge Fund Activity: Q4 2022 in Review
228 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2022, worth a combined $3.14B — up 12% from $2.81B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of RARE and 37 opened new positions — a net loss of 3 holders — while 58 trimmed existing stakes and 104 added.
The largest buyer was RTW Investments, adding an estimated $63.2M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $86.7M.
- 228 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2022, down from 233 in Q3 2022.
- Funds reported $3.14B of Ultragenyx Pharmaceutical stock for Q4 2022, up 12% quarter-over-quarter.
- 37 funds opened new Ultragenyx Pharmaceutical positions in Q4 2022 and 40 closed out, a net change of -3 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2022 was RTW Investments, an estimated $63.2M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2022 was T. Rowe Price Investment Management, an estimated $86.7M sold.
Based on aggregated 13F filings for Q4 2022.